Vertex Pharmaceuticals Inc (VRTX)

[surf1944]

1:28AM Vertex Pharma reviews 2010 business priorities (VRTX) 40.67 : Co provides an update on key 2010 business priorities in conjunction with the J.P. Morgan Healthcare Conference. Co also discusses recent progress in its lead development programs in hepatitis C virus infection and cystic fibrosis and outlined proof-of-concept clinical trials planned in other serious diseases for 2010. HCV: New Drug Application planned for telaprevir in second half of 2010, commercialization and launch preparedness activities ongoing. Cystic Fibrosis: Advancing development efforts in orphan disease of cystic fibrosis; Phase 3 STRIVE trial with VX-770 completes planned enrollment, VX-809 Phase 2 data expected in first quarter 2010. Pipeline: Proof-of-concept clinical trials planned for 2010 with novel combination regimens for hepatitis C and cystic fibrosis and with compounds for rheumatoid arthritis and epilepsy.